Plain-English translation of NCT05660395 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial examined , a new targeted cancer medication, in patients with relapsed or refractory diffuse large B-cell lymphoma or high-grade B-cell lymphoma who also have moderate or severe liver problems. The study aimed to figure out the right dose of this medication for patients whose livers don't work normally, since liver problems can affect how the body processes drugs.
When cancer medications are processed by the liver, liver damage or disease can change how the drug works in the body—it might build up to unsafe levels or not work effectively. This trial existed to understand how to safely use this new treatment in patients whose livers aren't working properly, a group that's often left out of cancer drug studies.
Participants would receive intravenous infusions of the medication once every three weeks for at least two treatment cycles (each cycle is 21 days), with the dose adjusted based on liver function level and how well the body tolerates the treatment. Doctors would monitor blood work, liver function, and side effects throughout the study to determine the safest and most effective dose for patients with liver problems. The study has been terminated, so it is no longer enrolling new participants.
AI-generated summary from trial data · Aug 12, 2026 · Not medical advice
United States
Brazil